Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.

ABSTRACT: Buprenorphine is used to treat opioid use disorder (OUD). Weekly and monthly subcutaneous long-acting buprenorphine injections (CAM2038) provide more stable buprenorphine plasma levels and reduce the treatment burden, misuse, and diversion associated with sublingual transmucosal buprenorphine formulations. To characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationship, a maximum inhibition (I_max) model was developed relating CAM2038 buprenorphine plasma concentration to drug liking maximum effect (E_max) visual analog scale (VAS; bipolar) score after intramuscular hydromorphone administration. Data included time-matched observations of buprenorphine plasma concentration and drug liking E_max VAS score after hydromorphone 18 mg administration in 47 n

SUBMITTER: Walsh SL 

PROVIDER: S-EPMC11039630 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature